We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00189254
Recruitment Status : Completed
First Posted : September 19, 2005
Last Update Posted : November 29, 2016
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of the study is to obtain recurrence rates and long-term safety data for patients who had been treating actinic keratoses on the face and scalp with 5 % Imiquimod Cream in a previous study.

Condition or disease Intervention/treatment Phase
Actinic Keratoses Drug: Imiquimod Phase 3

Study Design

Study Type : Observational
Estimated Enrollment : 72 participants
Time Perspective: Prospective
Official Title: A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1487-IMIQ Study
Study Start Date : April 2005
Primary Completion Date : November 2005
Study Completion Date : November 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Imiquimod
U.S. FDA Resources

Groups and Cohorts

Group/Cohort Intervention/treatment
Imiquimod 5% cream
No investigational treatments were given during this study.
Drug: Imiquimod
No defined treatments were given during this study.

Outcome Measures

Primary Outcome Measures :
  1. Efficacy [ Time Frame: one year after completion of study 1487-Imiq ]
    Efficacy was evaluated by counting AK lesions in the previous treatment area. Subjects at the 1-year follow-up visit with recurrence of lesion(s).

  2. Safety [ Time Frame: one year after completion of study 1487-Imiq ]
    Safety was evaluated by assessing the area of previous treatment for LSRs and skin quality

  3. Adverse Events [ Time Frame: one year after completion of study 1487-Imiq ]
    AEs considered by investigator to be possibly or probably related to the 1487-Imiq study medication were documented and recorded.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
At least 18 years old. Females of childbearing potential, with a negative urine pregnancy test, must have been willing to use a medically acceptable method of contraception during the treatment.

Inclusion Criteria:

  • 100% clearance of Actinic Keratosis (AK) lesions in the 1487 IMIQ study

Exclusion Criteria:

  • used any treatments in the previous treatment area within 24 hours prior to the follow-up visit
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00189254

Sponsors and Collaborators
MEDA Pharma GmbH & Co. KG
Study Chair: Study Coordinator Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
More Information

Responsible Party: MEDA Pharma GmbH & Co. KG
ClinicalTrials.gov Identifier: NCT00189254     History of Changes
Other Study ID Numbers: 1524-IMIQ
First Posted: September 19, 2005    Key Record Dates
Last Update Posted: November 29, 2016
Last Verified: April 2015

Keywords provided by MEDA Pharma GmbH & Co. KG:
1 year follow up

Additional relevant MeSH terms:
Keratosis, Actinic
Disease Attributes
Pathologic Processes
Skin Diseases
Precancerous Conditions
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Interferon Inducers